Niravam

Niravam is a brand name of alprazolam, approved by the FDA in the following formulation(s):

NIRAVAM (alprazolam - tablet, orally disintegrating; oral)

• 
  Manufacturer: UCB INC
  
  Approval date: January 19, 2005
  
  Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[RLD][AB], 2MG ^[AB]

Has a generic version of Niravam been approved?

A generic version of Niravam has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Niravam and have been approved by the FDA:

alprazolam tablet, orally disintegrating; oral

• 
  Manufacturer: ACTAVIS ELIZABETH
  
  Approval date: March 16, 2010
  
  Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]


• 
  Manufacturer: PAR PHARM
  
  Approval date: January 9, 2009
  
  Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Niravam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Rapidly dissolving robust dosage form
  Patent 6,024,981
  Issued: February 15, 2000
  Inventor(s): Khankari; Rajendra K. & Hontz; John & Chastain; Sara J. & Katzner; Leo
  Assignee(s): Cima Labs Inc.
  The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a non-direct compression filler and a relatively high lubricant content.
  
  Patent expiration dates:
  
  
  • April 9, 2018
    
    ✓ 
    Drug product
  
  



• 
  Rapidly dissolving robust dosage form
  Patent 6,221,392
  Issued: April 24, 2001
  Inventor(s): Khankari; Rajendra K. & Hontz; John & Chastain; Sara J. & Katzner; Leo
  Assignee(s): Cima Labs Inc.
  The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a nondirect compression filler and a relatively high lubricant content.
  
  Patent expiration dates:
  
  
  • April 9, 2018
    
    ✓ 
    Drug product
  
  

See also...

• Niravam Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Niravam Consumer Information (Cerner Multum)
• Niravam Advanced Consumer Information (Micromedex)
• Alprazolam Consumer Information (Drugs.com)
• Alprazolam Consumer Information (Wolters Kluwer)
• Alprazolam Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Alprazolam Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Alprazolam Solution Consumer Information (Wolters Kluwer)
• Alprazolam Consumer Information (Cerner Multum)
• Alti-Alprazolam Advanced Consumer Information (Micromedex)
• Gabazolamine-0.5 Advanced Consumer Information (Micromedex)
• Alprazolam Advanced Consumer Information (Micromedex)
• Alprazolam AHFS DI Monographs (ASHP)